Phase I/II Dose-escalation Study to Investigate Safety and Pharmacokinetics/ Pharmacodynamics of WX-554 in Patients With Solid Tumours
A Phase I/II, Open-label, Dose-escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the MEK Inhibitor WX-554 in Patients With Solid Tumours
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Belfast, United Kingdom, BT9 7AB
- Queen's University Belfast Cancer Centre
-
Glasgow, United Kingdom, G12 0YN
- Beatson West of Scotland Cancer Centre
-
Leeds, United Kingdom, LS9 7TF
- St James' Institute of Oncology
-
Manchester, United Kingdom, M20 4BX
- Christie NHS Foundation Trust, Oak Road Treatment Centre
-
Newcastle Upon Tyne, United Kingdom, NE7 7DN
- Sir Bobby Robson Cancer Trials Research Centre
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with advanced, metastatic and/or progressive solid tumours for whom there is no effective standard therapy available.
- Evaluable or measurable disease
- Has normal organ functions; is no greater than 2 on the ECOG Performance Scale
- life expectancy of >3 months
- negative hCG test in women of childbearing potential
Exclusion Criteria:
- Patients who received an investigational anti-cancer drug within 4 weeks of starting the study
- Patients who received major surgery, radiotherapy, or immunotherapy within 4 weeks of starting the study
- Clinically significant, unresolved toxicity from previous anti-cancer therapy Patients
- Patients who previously received a MEK inhibitor
- Presence of active gastrointestinal disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of drugs.
- Known medical history of retinal vein occlusion, intraocular pressure greater than 21 mm Hg or patient considered at risk of retinal vein thrombosis.
- Known HIV positivity or active hepatitis B or C infection.
- History of clinically significant cardiac condition
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: WX-554
|
Capsules of WX-554
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Part 1: Determination of the Optimal Biological Dose (OBD) by the assessment of ERK phosphorylation (pERK) in peripheral blood mononuclear cells (PBMC) and assessment of TNF-alpha in plasma.
Time Frame: Cycle 1 (21 days)
|
Cycle 1 (21 days)
|
|
Part 1: Determination of the Maximum Tolerated Dose (MTD) for WX-554 by the evaluation of DLTs in 3-6 patients at the end of 1 treatment cycle
Time Frame: Cycle 1 (21 days)
|
Cycle 1 (21 days)
|
|
Part 2: To further determine the safety and tolerability by evaluating the incidence and severity of adverse events and serious adverse events (as per CTCAE grading), changes in hematology and chemistry values, vital signs, ECGs.
Time Frame: expected average of 3-6 months
|
expected average of 3-6 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Assessment of PK variables maximum observed concentration (Cmax), minimum observed concentration (Cmin), time at which Cmax was present (tmax), Area Under Curve (AUC)
Time Frame: PK profile on day 1 and day 8
|
PK profile on day 1 and day 8
|
|
Assessment of ERK phosphorylation (pERK) in PBMC and tissue, assessment of TNF-alpha in plasma after oral intake of the OBD/MTD.
Time Frame: expected average of 3-6 months
|
expected average of 3-6 months
|
|
Tumour response evaluation using RECIST 1.1
Time Frame: expected average of 3-6 months
|
expected average of 3-6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Ruth Plummer, MD, Sir Bobby Robson Cancer Trials Research Centre
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- WX/80-003
- 2011-003408-19 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.